PDGFRB and pulmonary arterial hypertension: Given the fact that the PDGF is the predominant trigger in PASMCs’ proliferation and migration [16], it is not surprising that using receptor tyrosine kinase inhibitors, such as imatinib against the PDGF receptor (PDGFR), has been regarded as an attractive strategy to treat PAH.